Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 17:13:1252215.
doi: 10.3389/fonc.2023.1252215. eCollection 2023.

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience

Enikő Sebestyén  1 , Nóra Major  1 , Levente Bodoki  2 , Attila Makai  3 , Ingrid Balogh  1 , Gábor Tóth  4 , Zsuzsanna Orosz  3 , Péter Árkosy  1 , Attila Vaskó  3 , Katalin Hodosi  2 , Zoltán Szekanecz  2 , Éva Szekanecz  1
Affiliations

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience

Enikő Sebestyén et al. Front Oncol. .

Abstract

Objectives: Immune checkpoint inhibitors (ICIs) stimulate antitumor immune responses and, in parallel, they might trigger autoimmune and other immunopathological mechanisms eventually leading to immune-related adverse events (irAE). In our study, we assessed patients with malignancies who underwent anti-PD-1 treatment at the University of Debrecen, Clinical Center.

Patients and methods: Between June 2017 and May 2021, 207 patients started ICI treatment at our university. A total of 157 patients received nivolumab and 50 were treated with pembrolizumab. We looked for factors associated with the development of irAEs. In addition to correlation studies, we performed binary logistic regression analysis to determine, which factors were associated with irAEs. We also performed Forward Likelihood Ratio (LR) analysis to determine independent prognostic factors.

Results: At the time of data analysis, the mean duration of treatment was 2.03 ± 0.69 years. ROC analysis determined that 9 or more treatment cycles were associated with a significantly higher risk of irAEs. A total of 125 patients received ≥9 treatment cycles. Three times more patients were treated with nivolumab than pembrolizumab. Of the 207 patients, 66 (32%) developed irAEs. Among the 66 patients who developed irAEs, 36 patients (55%) developed one, 23 (35%) developed two, while 7 (10%) developed three irAEs in the same patient. The most common irAEs were thyroid (33 cases), dermatological (25 cases), pneumonia (14 cases) and gastrointestinal complications (13 cases). Patients who developed irAEs received significantly more treatment cycles (21.8 ± 18.7 versus 15.8 ± 17.4; p=0.002) and were younger at the start of treatment (60.7 ± 10.8 versus 63.4 ± 10.1 years; p=0.042) compared to patients without irAEs. Pembrolizumab-treated patients developed more but less severe irAEs compared to those receiving nivolumab.

Conclusion: ICI treatment is very effective, however, irAEs may develop. These irAEs might be related to the number of treatment cycles and the type of treated malignancy.

Keywords: Central-Eastern Europe; Hungary; anti-PD-1; immune-checkpoint inhibitors; immune-related adverse events; nivolumab; pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The distribution of indications for nivolumab and pembrolizumab treatment. Numbers show the number of patients with the given type of malignancy.
Figure 2
Figure 2
ROC analysis of the association of treatment cycles and the development of irAEs. The asterisk indicates the cut-off of 9 cycles. Nine or more treatment cycles as cut-off resulted in an increased risk for irAEs with an Odds ratio (OR) of 3.328 (95%CI: 1.008-1.042; p=0.004), a sensitivity of 72% and a specificity of 54%.
See this image and copyright information in PMC

References

    1. Szekanecz Z, Szekanecz É. Immunological and immunooncological role of PD-1 and PD-L1. Immunol Q (Budapest) (2017) 9(1):23–7.
    1. Dai S, Jia R, Zhang X, Fang Q, Huang L. The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol (2014) 290(1):72–9. doi: 10.1016/j.cellimm.2014.05.006 - DOI - PubMed
    1. Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol (2018) 14(10):569–79. doi: 10.1038/s41584-018-0074-9 - DOI - PubMed
    1. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol (2015) 33(17):1974–82. doi: 10.1200/JCO.2014.59.4358 - DOI - PMC - PubMed
    1. Szekanecz E, Szekanecz Z. [Autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment]. Hung Med J (2019) 160(23):887–95. - PubMed

LinkOut - more resources